Evaluation of the effect of hydroalcoholic and flavonoid-enriched extracts of Dracocephalum kotschyi on indomethacin-induced gastric ulcer in rats

Mohsen Minaiyan , Hassan Sadraei, Iman Yousefi, Sayed-Ebrahim Sajjadi, Ardeshir Talebi


Background and purpose: Dracocephalum kotschyi (Zaringiah) is a fragrant wild medicinal plant found in Iran. Traditionally, it is used for the treatment of rheumatism, asthma, and gastrointestinal ailments. So far no investigation has been done on the beneficial or side effects of D. kotschyi on peptic ulcer. Therefore, this research was performed to find out whether D. kotschyi extract would induce peptic ulcer or could alleviate existing peptic ulcer.  

Experimental approach: Effect of hydroalcoholic (DKHE) and flavonoid extracts (DKFE) of D. kotschyi were determined in normal or indomethacin-induced gastric ulcer rats (n = 6) and compared with the vehicle and ranitidine treated controls. All the treatments were carried out orally and 24 h later the stomach mucus was visually examined for peptic ulcers. A section of the stomach was taken for microscopic histopathological examinations while another section of the stomach was used for measurement of myeloperoxidase (MPO) and malondialdehyde (MDA) activities.

Findings/Results: Oral administration of the DKHE and DKFE alone, did not cause any sign of gastric ulcer induction. The D. kotschyi extracts not only didn’t aggravate the induced ulcer but also significantly prevented the severity of gastric ulcer induction by indomethacin. In addition, DKHE and DKFE inhibited MPO (up to 58.2%) and MDA (up to 44.2%) activities indicating their anti-inflammatory and antioxidant potential action on the stomach-induced ulcer.

Conclusion and implication: Usage of D. kotschyi extracts is not associated with gastric ulcer induction and its co-administration with NSAIDs would be beneficial for controlling both the inflammation and preventing gastric ulcer in diseases such as rheumatism.


Dracocephalum kotschyi; Gastric ulcer; Indomethacin; Malondialdehyde; Pepsin; Rats.

Full Text:



McQuaid KR. Drugs Used in the Treatment of Gastrointestinal Diseases. 14th ed. New York: McGraw Hill; 2018. pp: 1087-1094.

Sung JJY, Kuipers EJ, El‐Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29(9):938-946.

DOI: 10.1111/j.1365-2036.2009.03960.x.

Wei-Ping B, Hui-Bin M, Mao-Qiang M. Efficacy and safety of herbal medicines in treating gastric ulcer: a review. World J Gastroenterol. 2014;20(45):17020-17028.

DOI: 10.3748/wjg.v20.i45.17020.

Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. J Clin Med. 2019;8(2):179-197.

DOI: 10.3390/jcm8020179.

Naghibi F, Mosaddegh M, Mohammadi-Motamed M, Ghorbani A. Labiatae family in folk medicine in Iran: from ethnobotany to pharmacology. Iran J Pharm Res. 2010;4(2):63-79.

Sonboli A. Molecular characterization of Iranian Dracocephalum (Lamiaceae) species based on RAPD data material and methods plant material DNA extraction screening and PCR amplification with RAPD primers. Acta Biol Szegediensis. 2011;55(2):227-230.

Heydari P, Yavari M, Adibi P, Asghari G, Ghanadian SM, Dida GO, et al. Medicinal properties and active constituents of Dracocephalum kotschyi and its significance in Iran: a systematic review. Evid Based Complement Alternat Med. 2019;2019:9465309,1-14.

DOI: 10.1155/2019/9465309.

Sajjadi SE, Movahedian Atar AM, Yektaian A. Antihyperlipidemic effect of hydroalcoholic extract, and polyphenolic fraction from Dracocephalum kotschyi Boiss. Pharm Acta Helv. 1998;73(3):167-170.

DOI: 10.1016/s0031-6865(98)00016-8.

Eskandari M, Mohammadi J, Delaviz H, Hossieni E. The effects of hydroalcoholic extract of Dracocephalum kotschyi on blood glucose and lipid profile in diabetic rats. J Fasa Univ Med Sci. 2016;5(4):526-533.

Kalantar K, Gholijani N, Mousaei N, Yazdani M, Amirghofran Z. Investigation of Dracocephalum kotschyiplant extract on the effective inflammatory transcription factors and mediators in activated macrophages. Antiinflamm Antiallergy Agents Med Chem. 2018;17(1):39-49.

DOI: 10.2174/1871523017666180608081656.

Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N, Mahmoudian M. Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyi and a potential anti-cancer agent. Phytochemistry. 2005;66(13):1581-1592.

DOI: 10.1016/j.phytochem.2005.04.035.

Ashrafi B, Ramak P, Ezatpour B, Talei GR. Investigation on chemical composition, antimicrobial, antioxidant, and cytotoxic properties of essential oil from Dracocephalum kotschyi Boiss. Afr J Tradit Complement Altern Med. 2017;14(3):209-217.

DOI: 10.21010/ajtcam.v14i3.23.

Ghavam M, Manconi M, Manco ML, Bachetta G. Extraction of essential oil from Dracocephalum kotschyi Boiss. (Lamiaceae), identification of two active compounds and evaluation of the antimicrobial properties. J Ethnopharmacol. 2021;267:1-26.


Sadraei H, Asghari G, Kasiri F. Comparison of antispasmodic effects of Dracocephalum kotschyi essential oil, limonene and alpha-terpineol. Res Pharm Sci. 2015;10(2):109-116.

Golshani S, Karamkhani F, Monsef-Esfehani HR, Abdollahi M. Antinociceptive effects of the essential oil of Dracocephalum kotschyi in the mouse writhing test. J Pharm Pharm Sci. 2004;7(1):76-79.

Faham N, Javidnia K, Bahmani M, Amirghofran Z. Calycopterin, an immunoinhibitory compound from the extract of Dracocephalum kotschyi. Phytother Res. 2008;22(9):1154-1158.

DOI: 10.1002/ptr.2382.

Sadraei H, Asghari G, Khanabadi M, Minaiyan M. Anti-inflammatory effect of apigenin and hydroalcoholic extract of Dracocephalum kotschyi on acetic acid-induced colitis in rats. Res Pharm Sci. 2017;12(4):322-329.

DOI: 10.4103/1735-5362.212050.

Serafini M, Peluso I, RaguzziniA. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69(3):273-278.

DOI: 10.1017/S002966511000162X.

Kamali M, Khosroyar S, Kamali H, Ahmadzade Sani T, Mohammadi A. Phytochemical screening and evaluation of antioxidant activities of Dracocephalum kotschyi and determination of its luteolin content. Avicenna J Phytomed 2016;6(4):425-433.

DOI: 10.22038/ajp.2016.6377.

Sadraei H, Ghanadian SM, Moazeni S. Inhibitory effect of hydroalcoholic and flavonoids extracts of Dracocephalum kotschyi, and its components luteolin, apigenin and apigenin-4’-galactoside on intestinal transit in mice. J Herbmed Pharmacol. 2019;8(1):8-13.

DOI: 10.15171/jhp.2019.02.

Sadraei H, Ghanadian SM, Asghari G, Gavahian A. Bronchodilator effect of apigenin and luteolin, two components of Dracocephalum kotschyi on isolated rabbit trachea. J Herbmed Pharmacol. 2019;8(4):281-286.

DOI: 10.15171/jhp.2019.41

Choi JR, Lee CM, Jung ID, Lee JS, Jeong YI, Chang JH, et al. Apigenin protects ovalbumin-induced asthma through the regulation of GATA-3 gene. Int Immunopharmacol. 2009;9(7-8):918-924.

DOI: 10.1016/j.intimp.2009.03.018.

Sadraei H, Ghanadian M, Asghari G, Sekhavati N. Antispasmodic activity of apigenin and luteolin, two components of Dracocephalum kotschyi extract, on rat ileum contractions. J Herbmed Pharmacol. 2018;7(2):100-105.

DOI: 10.15171/jhp.2018.17.

Buttgereit F, Saag KG, Cutolo M, da Silva JA, Bijlsma JWJ. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;34(1):14-21.

DOI: 10.1080/03009740510017706.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(11):1-278.

DOI: 10.3310/hta12110.

Handa SS, Khanuja SP, Lango G, Rakesh DU. Extraction Technologies for Medicinal and Aromatic Plants. Italy, Trieste: Earth, Environmental and Marine Sciences and Technologies International Centre for Science and High Technology; 2008. pp: 32-35.

Ghasemi Dehkordi NA, Sajadi SE, Ghanadi AR, Amanzadeh Y, Azadbakht M, Asghari GH, et al. Iranian herbal pharmacopoeia. Hakim Res J. 2003;6(3):63-69.

Vogel HG. Drug Discovery and Evaluation, Pharmacologic Assays. 2nd ed. Verlag Berlin Heidelberg: Springer; 2002. pp: 869.

Minaiyan M, Sajjadi SE, Amini K. Antiulcer effects of Zataria multiflora Boiss. on indomethacin-induced gastric ulcer in rats. Avicenna J Phytomed. 2018;8(5):408-415.

Parvan M, Sajjadi SE, Minaiyan M. Protective effect of two extracts of Cydonia oblonga Miller (Quince) fruits on gastric ulcer induced by indomethacin in rats. Int J Prev Med. 2017;8:58-63.

DOI: 10.4103/ijpvm.IJPVM_124_17.

Motavallian A, Minaiyan M, Rabbani M, Mahzouni P, Andalib S. Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis. Res Pharm Sci. 2019;14(3):228-236.

DOI: 10.4103/1735-5362.258489.

Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738.

DOI: 10.1038/ajg.2009.115.

Somasundaram S, Sigthorsson G, Simpson R, Watts J, Jacob M, Tavares I, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther. 2000;14(5):639-650.

DOI: 10.1046/j.1365-2036.2000.00723.x.

Negm AA, Furst DE. Non-steroidal Anti-inflammatory Drugs, Disease Modifying Anti-rheumatoid Drugs, Non-opioid Analgesics and Drugs Used in Gout. 14th ed. New York: McGraw Hill; 2018. pp: 644-646.

Hämäläinen M, Nieminen R, Asmawi MZ, Vuorela P, Vapaatalo H, Moilanen E. Effects of flavonoids on prostaglandin E2 production and on COX-2 and mPGES-1 expressions in activated macrophages. Planta Med. 2011;77(13):1504-1511.

DOI: 10.1055/s-0030-1270762.

Gohari AR, Saeidnia S, Matsuo K, Uchiyama N, Yagura T, Ito M, et al. Flavonoid constituent of Dracocephalum kotschyi growing in Iran and their trypanocidal activity. Nat Med. 2003;57(6):250-252.

Faith M, Sukumaran A, Pulimood AB, Jacob M. How reliable an indicator of inflammation is myeloperoxidase activity? Clin Chim Acta. 2008;396(1-2):23-25.

DOI: 10.1016/j.cca.2008.06.016.

Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. Quimica Nova. 2009;32(1):169-174.

DOI: 10.1590/S0100-40422009000100032.

Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem. 2005;38(10):951-955.

DOI: 10.1016/j.clinbiochem.2005.06.010.

Tunon MJ, Garcia-Mediavilla MV, Sanchez-Campos S, Gonzalez-Gallego J. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr Drug Metab. 2009;10(3):256-271.

DOI: 10.2174/138920009787846369.

Wang YC, Huang KM. In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells. Food Chem Toxicol. 2013;53:376-383.

DOI: 10.1016/j.fct.2012.12.018.

Funakoshi-Tago M, Nakamura K, Tago K, Mashino T, Kasahara T. Anti-inflammatory activity of structurally related flavonoids, apigenin, luteolin and fisetin. Int Immunopharmacol. 2011;11(9):1150-1109.

DOI: 10.1016/j.intimp.2011.03.012.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.